Prospecting for Novel Plant-Derived Molecules of Rauvolfia serpentina as Inhibitors of Aldose Reductase, a Potent Drug Target for Diabetes and Its Complications

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Pathania, Shivalika ^a   Randhawa, Vinay ^a   Bagler, Ganesh ^a  

^a CSIR INSTITUTE OF HIMALAYAN BIORESOURCE TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIMETHOXYBENZOQUINONE; 7 DEHYDROSITOSTEROL; AJMALICINE; AJMALINE; AJMALININE; ALDOSE REDUCTASE INHIBITOR; ALSTONINE; CHANDRINE; CORYNANTHINE; DESERPIDINE; INDOBINE; INDOBININE; ISOAJMALINE; OPHIOXYLIN; PAPAVERINE; PLANT MEDICINAL PRODUCT; RAUVOLFIA SERPENTINA EXTRACT; RAUWOLSCINE; RENOXIDINE; RESCINNAMINE; RESERPINE; SARPAGINE; SERPENTINE; SERPENTININE; SERPININE; STIGMASTEROL; TETRAPHYLLICINE; THEBAINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE;

ARTICLE; COMPLEX FORMATION; DIABETES MELLITUS; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; RAUVOLFIA SERPENTINA; RAUWOLFIA; STRUCTURE ACTIVITY RELATION;

ALDEHYDE REDUCTASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; HYPERGLYCEMIA; MOLECULAR DOCKING SIMULATION; OXIDATIVE STRESS; PLANT EXTRACTS; RAUWOLFIA; REPRODUCIBILITY OF RESULTS; ROC CURVE; STRUCTURE-ACTIVITY RELATIONSHIP;

RAUVOLFIA SERPENTINA;

EID: 84876252310     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061327     Document Type: Article

References (75)

1. Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos V, (2009) Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Current Medicinal Chemistry 16: 734-752 doi:10.2174/092986709787458362.
2. Van Dieren S, Beulens J, Van der Schouw Y, Grobbee D, Neal B, (2010) The global burden of diabetes and its complications: an emerging pandemic. European Journal of Cardiovascular Prevention and Rehabilitation 17Suppl 1: S3-8 doi:10.1097/01.hjr.0000368191.86614.5a.
3. Brownlee M, (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820 doi:10.1038/414813a.
4. Wild S, Roglic G, Green A, Sicree R, King H, (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053 doi:10.2337/diacare.27.5.1047.
5. Kinoshita J, (1990) A thirty year journey in the polyol pathway. Experimental Eye Research 50: 567-573 doi:10.1016/0014-4835(90)90096-D.
6. Yabe Nishimura C, (1998) Aldose Reductase in Glucose Toxicity: A Potential Target for the Prevention of Diabetic Complications. Pharmacological Reviews 50: 21-33.
7. Tang W, Martin K, Hwa J, (2012) Aldose reductase, oxidative stress, and diabetic mellitus. Frontiers in Pharmacology 3: 1-8 doi:10.3389/fphar.2012.00087.
8. Qiu L, Lin J, Xu F, Gao Y, Zhang C, et al. (2012) Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-α and ameliorates hepatosteatosis in diabetic db/db mice. Experimental Diabetes Research 2012: 1-8 doi:10.1155/2012/789730.
9. Oates PJ, (2008) Aldose reductase, still a compelling target for diabetic neuropathy. Current Drug Targets 9: 14-36 doi:10.2174/138945008783431781.
10. Srivastava SK, Ramana K V, Bhatnagar A, (2005) Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocrine Reviews 26: 380-392 doi:10.1210/er.2004-0028.
11. Kraemer O, Hazemann I, Podjarny A, Klebe G, (2004) Virtual screening for inhibitors of human aldose reductase. Proteins: Structure, Function, and Bioinformatics 55: 814-823 doi:10.1002/prot.20057.
12. Kador P, Kinoshita J, Sharpless N, (1985) Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. Journal of Medicinal Chemistry 28: 841-849 doi:10.1021/jm00145a001.
13. Saraswat M, Muthenna P, Suryanarayana P, Petrash J, Reddy G, (2008) Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pacific Journal of Clinical Nutrition 17: 558-565.
14. Ramunno A, Cosconati S, Sartini S, Maglio V, Angiuoli S, et al. (2012) Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step. European Journal of Medicinal Chemistry 51: 216-226 doi:10.1016/j.ejmech.2012.02.045.
15. Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y, (1996) Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: Multicenter study. Journal of Diabetes and its Complications 10: 168-172 doi:10.1016/1056-8727(96)00113-4.
16. Steele JW, Faulds D, Goa KL, (1993) Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus. Drugs & Aging 3: 532-555 doi:10.2165/00002512-199303060-00007.
17. Giannoukakis N, (2003) Fidarestat (Sanwa Kagaku/NC Curex/Sankyo). Current Opinion in Investigational Drugs 4: 1233-1239.
18. Srivastava S, Yadav U, Reddy A, Saxena A, Tammali R, et al. (2011) Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chemico-Bological Interactions 191: 330-338 doi:10.1016/j.cbi.2011.02.023.
19. Costantino L, Rastelli G, Vianello P, Cignarella G, Barlocco D (1999) AID-MED2>3.0.CO;2-7.
20. Foppiano M, Lombardo G, (1997) Worldwide pharmacovigilance systems and tolrestat withdrawal. The Lancet 349: 399-400 doi:10.1016/S0140-6736(97)80018-9.
21. Schemmel K, Padiyara R, D'Souza J, (2010) Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. Journal of Diabetes and its Complications 24: 354-360 doi:10.1016/j.jdiacomp.2009.07.005.
22. Hung HY, Qian K, Morris Natschke SL, Hsu CS, Lee KH, (2012) Recent discovery of plant-derived anti-diabetic natural products. Natural Product Reports 29: 580-606 doi:10.1039/c2np00074a.
23. Akileshwari C, Muthenna P, Nastasijević B, Joksić G, Petrash JM, et al. (2012) Inhibition of aldose reductase by Gentiana lutea extracts. Experimental Diabetes Research 2012: 1-8 doi:10.1155/2012/147965.
24. Puppala M, Ponder J, Suryanarayana P, Reddy G, Petrash J, et al. (2012) The isolation and characterization of β-glucogallin as a novel aldose reductase inhibitor from Emblica officinalis. PloS One 7: 1-9 doi:10.1371/journal.pone.0031399.
25. Naeem S, Hylands P, Barlow D, (2012) Construction of an Indonesian herbal constituents database and its use in Random Forest modelling in a search for inhibitors of aldose reductase. Bioorganic & Medicinal Chemistry 20: 1251-1258 doi:10.1016/j.bmc.2011.12.033.
26. Barnes EC, Choomuenwai V, Andrews KT, Quinn RJ, Davis RA, (2012) Design and synthesis of screening libraries based on the muurolane natural product scaffold. Organic & Biomolecular Chemistry 10: 4015-4023 doi:10.1039/c2ob00029f.
27. Dey A, De J, (2011) Ethnobotanical aspects of Rauvolfia serpentina (L). Benth. ex Kurz. in India, Nepal and Bangladesh. Journal of Medicinal Plants Research 5: 144-150.
28. Pant K, Joshi S, (2008) Rapid Multiplication of Rauvolfia serpentina Benth. ex. kurz through tissue culture. Scientific World 6: 58-62 doi:10.3126/sw.v6i6.2635.
29. Qureshi S, Nawaz A, Udani S, Azmi B, (2009) Hypoglyceamic and Hypolipidemic Activities of Rauwolfia serpentina in Alloxan-Induced Diabetic Rats. International Journal of Pharmacology 5: 323-326 doi:10.3923/ijp.2009.323.326.
30. Azmi M, Qureshi A, (2012) Methanolic Root Extract of Rauwolfia serpentina Improves the Glucose Tolerance in Wister Mice. Journal of Food and Drug Analysis 20: 484-488 doi:10.6227/jfda.2012200208.
31. Xie HZ, Li LL, Ren JX, Zou J, Yang L, et al. (2009) Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorganic & medicinal chemistry letters 19: 1944-1949 doi:10.1016/j.bmcl.2009.02.049.
32. Rastelli G, Ferrari AM, Costantino L, Gamberini MC, (2002) Discovery of new inhibitors of aldose reductase from molecular docking and database screening. Bioorganic & medicinal chemistry 10: 1437-1450 doi:10.1016/S0968-0896(01)00410-2.
33. Randhawa V, Bagler G, (2012) Identification of SRC as a potent drug target for asthma, using an integrative approach of protein interactome analysis and in silico drug discovery. OMICS: A Journal of Integrative Biology 16: 513-526 doi:10.1089/omi.2011.0160.
34. Villacañas O, Pérez JJ, Rubio-Martínez J, (2002) Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through Molecular Dynamics simulations. Journal of Biomolecular Structure & Dynamics 20: 347-358 doi:10.1080/07391102.2002.10506853.
35. Good A, Mason J (2007) Three dimensional structure database searches. In: Lipkowitz KB, Boyd DB, editors. Reviews in Computational Chemistry. Hoboken, NJ, USA: John Wiley & Sons, Inc., Vol. 7. doi:10.1002/9780470125847.ch2.
36. Alonso H, Bliznyuk AA, Gready JE, (2006) Combining docking and molecular dynamic simulations in drug design. Medicinal Research Reviews 26: 531-568 doi:10.1002/med.20067.
37. Irwin J, Shoichet B, (2005) ZINC- A Free Database of Commercially Available Compounds for Virtual Screening. Journal of Chemical Information and Modeling 45: 177-182 doi:10.1021/ci049714.
38. A database on antidiabetic plants. (2012). Available:http://herbalmedicinalplants.org/index.php.Accessed 27 Sept 2012.
39. GLOBinMeD-Global Information Hub On Integrated Medicine. (2007). Available:http://www.globinmed.com/index.php?option=com_content&view=article&id=79110:rauvolfia-serpentina-benth&catid=720:r#6.Accessed 27 Sept 2012.
40. INDIA HERBS (CardiofyTM)- Cardiovascular System Support. (2002). Available:http://www.cardiofy.com/index.htm.Accessed 4 October 2012.
41. Buckingham J (2011) Dictionary of Natural Products on CD-ROM. Chapman and Hall/CRC.
42. Zaidi SSA (1986) Studies in the alkaloidal constituents of the roots of rauwolfia serpentina benth with particular regional variations and synthetic extensions of von braun (BrCN) reaction on alkaloidal and simpler organic bases. University of Karachi.
43. Haider SI (1986) Extended studies in the alkaloidal constituents of Rauwolfia serpentina from thailland and synthetic extensions of Von braun (BrCN) reaction on alkaloidal and simpler organic bases University of Karachi.
44. Cordell G (1998) The Alkaloids. 52nd ed. San Diego, USA: Academic Press.
45. Rodrigo R, Holmes H, Manske R (1965) The Alkaloids: Chemistry and Physiology. 4th ed. Newyork, London: Academic Press.
46. Manske R (1965) The Alkaloids: Chemistry and Physiology. 8th ed. Newyork, London: Academic Press.
47. O'Boyle N, Banck M, James C, Morley C, Vandermeersch T, et al. (2011) Open Babel: An open chemical toolbox. Journal of Cheminformatics 3: 1-14 doi:10.1186/1758-2946-3-33.
48. Trott O, Olson A, (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 31: 455-461 doi:10.1002/jcc.21334.
49. Morris GM, Huey R, Olson AJ (2008) Using AutoDock for ligand-receptor docking. Current Protocols in Bioinformatics 24: Unit 8.14. doi:10.1002/0471250953.bi0814s24.
50. Howard E, Sanishvili R, Cachau R, Mitschler A, Chevrier B, et al. (2004) Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 Å. Proteins: Structure, Function, and Bioinformatics 55: 792-804 doi:10.1002/prot.20015.
51. Huang N, Shoichet BK, Irwin JJ, (2006) Benchmarking sets for molecular docking. Journal of Medicinal Chemistry 49: 6789-6801 doi:10.1021/jm0608356.
52. Sing T, Sander O, Beerenwinkel N, Lengauer T, (2005) ROCR: visualizing classifier performance in R. Bioinformatics. 21: 3940-3941 doi:10.1093/bioinformatics/bti623.
53. Laskowski R, Swindells M, (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. Journal of Chemical Information and Modeling 51: 2778-2786 doi:10.1021/ci200227u.
54. Berendsen HJC, Van der Spoel D, Van Drunen R, (1995) GROMACS: A message-passing parallel molecular dynamics implementation. Computer Physics Communications 91: 43-56 doi:10.1016/0010-4655(95)00042-E.
55. Schüttelkopf AW, Van Aalten DMF, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica Section D Biological Crystallography 60: 1355-1363 doi:10.1107/S0907444904011679.
56. Berendsen HJC, Postma JPM, Gunsteren WF Van, Hermans J (1981) Interaction models for water in relation to protein hydration. In: Pullman B, editor. Intermolecular Forces. Dordrecht, The Netherlands: D Reidel Publishing Company. 331-342.
57. Scott WRP, Hu PH, Tironi IG, Mark AE, Billeter SR, et al. (1999) The GROMOS Biomolecular Simulation Program Package. The Journal of Physical Chemistry A 103: 3596-3607 doi:10.1021/jp984217f.
58. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, et al. (1995) A smooth particle mesh Ewald method. The Journal of Chemical Physics 103: 8577-8593 doi:10.1063/1.470117.
59. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM (1997) AID-JCC4>3.0.CO;2-H.
60. Miyamoto S, Kollman PA, (1992) Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. Journal of Computational Chemistry 13: 952-962 doi:10.1002/jcc.540130805.
61. Berendsen HJC, Postma JPM, Van Gunsteren WF, DiNola A, Haak JR, (1984) Molecular dynamics with coupling to an external bath. The Journal of Chemical Physics 81: 3684-3690 doi:10.1063/1.448118.
62. Rosén J, Johan G, Sorel M, Anders B, Tudor I O, (2009) Novel chemical space exploration via natural products. Journal of Medicinal Chemistry 52: 1953-1962 doi:10.1021/jm801514w.
63. Cereto-Massagué A, Guasch L, Valls C, Mulero M, Pujadas G, et al. (2012) DecoyFinder: an easy-to-use python GUI application for building target-specific decoy sets. Bioinformatics 28: 1661-1662 doi:10.1093/bioinformatics/bts249.
64. Lipinski CA, (2000) Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods 44: 235-249 doi:10.1016/S1056-8719(00)00107-6.
65. Yap BK, Buckle MJC, Doughty SW, (2012) Homology modeling of the human 5-HT1A, 5-HT 2A, D1, and D2 receptors: model refinement with molecular dynamics simulations and docking evaluation. Journal of Molecular Modeling 18: 3639-3655 doi:10.1007/s00894-012-1368-5.
66. Triballeau N, Acher F, Brabet I, Pin JP, Bertrand HO, (2005) Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. Journal of medicinal chemistry 48: 2534-2547 doi:10.1021/jm049092j.
67. Cole J, Murray C, Nissink J, Taylor R, Taylor R, (2005) Comparing protein-ligand docking programs is difficult. Proteins: Structure, Function, and Bioinformatics 60: 325-332 doi:10.1002/prot.20497.
68. Kitchen D, Decornez H, Furr J, Bajorath J, (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews Drug Discovery 3: 935-949 doi:10.1038/nrd1549.
69. Lengauer T, Lemmen C, Rarey M, Zimmermann M, (2004) Novel technologies for virtual screening. Drug Discovery Today 9: 27-34 doi:10.1016/S1359-6446(04)02939-3.
70. Costantino L, Ferrari AM, Gamberini MC, Rastelli G, (2002) Nitrophenyl Derivatives as Aldose Reductase Inhibitors. Bioorganic & Medicinal Chemistry 10: 3923-3931 doi:10.1016/S0968-0896(02)00318-8.
71. Nikolova N, Jaworska J, (2003) Approaches to Measure Chemical Similarity - a Review. QSAR & Combinatorial Science 22: 1006-1026 doi:10.1002/qsar.200330831.
72. Logendra S, Ribnicky DM, Yang H, Poulev A, Ma J, et al. (2006) Bioassay-guided isolation of aldose reductase inhibitors from Artemisia dracunculus. Phytochemistry 67: 1539-1546 doi:10.1016/j.phytochem.2006.05.015.
73. Wang Z, Ling B, Zhang R, Suo Y, Liu Y, et al. (2009) Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase. Journal of Molecular Graphics & Modelling 28: 162-169 doi:10.1016/j.jmgm.2009.06.003.
74. Rastelli G, Ferrari AM, Costantino L, Gamberini MC, (2002) Discovery of new inhibitors of aldose reductase from molecular docking and database screening. Bioorganic & medicinal chemistry 10: 1437-1450 doi:10.1016/S0968-0896(01)00410-2.
75. Sakkiah S, Thangapandian S, Lee KW, (2012) Pharmacophore modeling, molecular docking, and molecular dynamics simulation approaches for identifying new lead compounds for inhibiting aldose reductase 2. Journal of molecular modeling 18: 3267-3282 doi:10.1007/s00894-011-1247-5.